来凯医药再涨超15%公司已与礼来达成合作联合开发LAE102

动脉网
May 21, 2025

来凯医药与礼来合作开发LAE102,旨在解决减重治疗中肌肉流失问题,推动体重管理发展,其股价涨幅超15%。公司已启动七项临床试验,专注于肥胖和肿瘤治疗。LAE102是自主研发的单克隆抗体,可促进肌肉再生和减少脂肪,具有优质体重控制潜力。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10